By Fineline Cube Tasly Pharma Co., Ltd (SHA: 600535) announced plans to enter a collaboration agreement with the Beijing Neurosurgical Institute and Beijing Rencheng Neurotumor Biotechnology Engineering Research Center Co., Ltd to jointly advance the development and industrialization of a dual-target CAR-T therapy for recurrent glioblastoma. The autologous CAR-T product, targeting CD44 and/or CD133, received clinical trial approval in April 2025 and has already initiated Phase I clinical studies.
Partnership Structure & Financial Framework
| Component | Details |
|---|---|
| Lead Developer | Tasly Pharma Co., Ltd (SHA: 600535) |
| Technology Holder | Beijing Neurosurgical Institute |
| R&D Partner | Beijing Rencheng Neurotumor Biotechnology Engineering Research Center |
| Total R&D Investment | RMB 240 million (USD 35.2 million) |
| Cost Sharing | Proportional allocation based on responsibilities and development stages |
| Development Stage | Phase I clinical trials (initiated) |
Product Profile & Clinical Status
- Therapy Type: Autologous CAR-T cell therapy
- Targets: CD44 and/or CD133 – dual-target approach for enhanced tumor specificity
- Indication: Recurrent glioblastoma – one of the most aggressive and treatment-resistant brain cancers
- Regulatory Milestone: Clinical trial approval granted April 2025 by NMPA
- Current Status: Phase I clinical studies actively enrolling patients
- Unmet Need: Addresses critical gap in recurrent glioblastoma treatment with median survival of 6–9 months post-recurrence
Role Allocation & Commercial Rights
Tasly Pharma Responsibilities
- Marketing Authorization Holder (MAH) status
- Lead all R&D coordination and regulatory filing activities
- Full commercialization strategy and execution
- Exclusive ownership of manufacturing and commercial rights
Beijing Neurosurgical Institute Role
- Core technology holder with patent ownership
- Ongoing R&D support and scientific guidance
- Clinical expertise in neurosurgical oncology applications
Beijing Rencheng Bio Contribution
- Technical and financial support for specific R&D stages
- Risk-sharing partnership model
- Profit participation proportional to actual R&D investment alongside Tasly
Strategic Implications
- CAR-T Market Entry: Positions Tasly as a serious player in China’s emerging cell therapy market
- Neuro-Oncology Focus: Addresses high-value, high-unmet-need indication with limited therapeutic options
- Dual-Target Innovation: CD44/CD133 targeting may overcome limitations of single-target CAR-T approaches in solid tumors
- Industrialization Pathway: Clear commercial rights structure enables efficient scale-up and market access planning
Market Context
- Glioblastoma Market: Global recurrent glioblastoma market estimated at $1.2 billion annually with premium pricing potential for effective therapies
- China Cell Therapy Landscape: Growing regulatory support for advanced therapy medicinal products (ATMPs) with expedited pathways for innovative approaches
- Competitive Positioning: Among the first dual-target CAR-T therapies specifically developed for glioblastoma in China
Financial Impact
The RMB 240 million investment represents a strategic allocation of capital toward high-value oncology innovation. Tasly maintains full commercial control while sharing development risk through the collaborative partnership structure.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial expectations for the dual-target CAR-T therapy. Actual results may differ due to risks inherent in cell therapy development, including clinical trial outcomes, manufacturing challenges, regulatory approvals, and competitive dynamics.-Fineline Info & Tech